Most clinical research institutions believe their study start-up delays are a technology problem. They aren't. It’s a fragmentation problem, and many technologies ha...

The globalisation of clinical research is accelerating, with a growing share of trials now conducted in emerging markets across Asia, Latin America and Africa. Ventu...

The primary goal of drug safety, or pharmacovigilance, is the detection, assessment, understanding and prevention of adverse effects or any other drug-related proble...

Risk-based quality management (RBQM) is now widely recognised as crucial to improving data quality and clinical trial efficiency. Regulatory backing and increasing c...

Reliable medication intake is a fundamental prerequisite for both therapeutic success and the validity of clinical trial outcomes. Deviations from prescribed regimen...

More than 300 million people worldwide live with a rare disease, representing up to 5.9% of the global population. With over 6,000 distinct conditions, 72% of which ...

Everything in a clinical trial should be designed to optimise the success of meeting the trial’s endpoints. This goal starts with developing a flawless protocol, whi...

Rare diseases collectively affect an estimated 300 - 400 million people worldwide, despite each individual condition impacting only a small patient population. While...

A year ago, the US Food and Drug Administration (FDA) launched a new “ultra-fast” review programme intended to dramatically shorten review times for drug and biologi...

In the past year, China has rapidly emerged as a key strategic consideration for sponsors planning to run global studies. That marks a sharp shift from the tradition...